Learn More
GUIDELINES In patients with hypertension associated with renovascular disease, pharmacological inhibition of the renin–angiotensin system effectively and safely lowers blood pressure in most patients (Level II evidence). (Suggestions are based on Level III and IV evidence) • In patients with established evidence-based indications for inhibition of the(More)
Obesity is an independent risk factor for chronic kidney disease (CKD). The mechanisms linking obesity and CKD include systemic changes such as high blood pressure and hyperglycemia, and intrarenal effects relating to lipid accumulation. Normal lipid metabolism is integral to renal physiology and disturbances of renal lipid and energy metabolism are(More)
AIM Activation of the master energy-regulator AMP-activated protein kinase (AMPK) in the heart reduces the severity of ischemia-reperfusion injury (IRI) but the role of AMPK in renal IRI is not known. The aim of this study was to determine whether activation of AMPK by acute renal ischemia influences the severity of renal IRI. METHODS AMPK expression and(More)
Mutations of the intrinsic lysosomal membrane protein SCARB2 cause action myoclonus-renal failure syndrome (AMRF syndrome), a rare disease characterized by renal and neurological manifestations. In this study, examination of Cos7 cells transfected with SCARB2 cDNA derived from two patients with AMRF syndrome showed that the resultant protein was truncated(More)
(Suggestions are based primarily on Level III and IV evidence) • Gadolinium-enhanced magnetic resonance angiography (MRA) is highly sensitive in detecting atherosclerotic renal artery stenosis (RAS) and is significantly more accurate in excluding the disease. Gadolinium-based imaging should be avoided in patients with glomerular filtration <30 mL/min per(More)
GUIDELINES a. At 5 years (median 34 months), correction of renal artery stenosis (RAS), by balloon angioplasty with or without stenting (no distal protection) has no beneficial effect on blood pressure (BP) compared with medical therapy and is associated with an adverse event rate of 10–25%. (Level I Evidence) b. At 5 years (median 34 months), correction of(More)
(Suggestions are based primarily on Level III and IV evidence) • Distal protection devices should be considered for patients requiring renal artery angioplasty to prevent renal atheroembolism. Discussion between the nephrologist and interventional radiologist (and other relevant specialists) regarding the benefits and harms of distal protection in this(More)
(Suggestions are based on Level III and IV evidence) • Atherosclerotic renovascular stenosis is a potentially progressive disease. • Risk factors for progressive stenosis and renal artery occlusion include: – uncontrolled systolic hypertension (>160 mmHg) – diabetes mellitus – high grade (>70%) ipsilateral and contralateral ath-erosclerotic renal vascular(More)
  • 1